These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19519337)

  • 1. Novel targeted radiosensitisers in cancer treatment.
    Zaidi SH; Huddart RA; Harrington KJ
    Curr Drug Discov Technol; 2009 Jun; 6(2):103-34. PubMed ID: 19519337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
    van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
    Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.
    Chinnaiyan P; Allen GW; Harari PM
    Semin Radiat Oncol; 2006 Jan; 16(1):59-64. PubMed ID: 16378908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
    Caponigro F; Basile M; de Rosa V; Normanno N
    Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
    You L; Liu C; Tang H; Liao Y; Fu S
    Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in gynecologic cancers.
    Chon HS; Hu W; Kavanagh JJ
    Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New targeted therapies for anaplastic thyroid cancer.
    Antonelli A; Fallahi P; Ulisse S; Ferrari SM; Minuto M; Saraceno G; Santini F; Mazzi V; D'Armiento M; Miccoli P
    Anticancer Agents Med Chem; 2012 Jan; 12(1):87-93. PubMed ID: 22043992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer.
    Singh I; Amin H; Rah B; Goswami A
    Front Biosci (Schol Ed); 2013 Jan; 5(1):231-46. PubMed ID: 23277048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
    Auberger J; Loeffler-Ragg J; Wurzer W; Hilbe W
    Curr Cancer Drug Targets; 2006 Jun; 6(4):271-94. PubMed ID: 16848720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.
    Urtasun N; Vidal-Pla A; Pérez-Torras S; Mazo A
    BMC Cancer; 2015 Apr; 15():223. PubMed ID: 25886138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel mechanisms of regulation of IGF-1R action: functional and therapeutic implications.
    Worrall C; Nedelcu D; Serly J; Suleymanova N; Oprea I; Girnita A; Girnita L
    Pediatr Endocrinol Rev; 2013 Jul; 10(4):473-84. PubMed ID: 23957198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor tyrosine kinase signaling in cancer radiotherapy and its targeting for tumor radiosensitization.
    Bhattacharya P; Shetake NG; Pandey BN; Kumar A
    Int J Radiat Biol; 2018 Jul; 94(7):628-644. PubMed ID: 29775397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy of the insulin-like growth factor-1 receptor in cancer.
    Paz K; Hadari YR
    Comb Chem High Throughput Screen; 2008 Jan; 11(1):62-9. PubMed ID: 18220543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.
    Bischoff P; Altmeyer A; Dumont F
    Expert Opin Ther Pat; 2009 May; 19(5):643-62. PubMed ID: 19441939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of novel selective-spectrum kinase inhibitors in oncology.
    Lorusso PM; Eder JP
    Expert Opin Investig Drugs; 2008 Jul; 17(7):1013-28. PubMed ID: 18549338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.
    Xue M; Cao X; Zhong Y; Kuang D; Liu X; Zhao Z; Li H
    Curr Pharm Des; 2012; 18(20):2901-13. PubMed ID: 22571659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G; Ciardiello F; Gasparini G
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.